ER-positive/HER2-negative breast cancer
Clinical research in ER-positive, HER2-negative breast cancer spans advanced and metastatic disease, with attention to endocrine-resistant disease and ESR1-mutated tumours.
- Advanced ER+/HER2- breast cancer
- Metastatic breast cancer
- ESR1-mutated advanced breast cancer
- Endocrine therapy resistance
Research also includes treatment settings after prior CDK4/6 inhibitor exposure and disease that has progressed despite hormonal therapy.
Early breast cancer and recurrence prevention
Studies extend into early breast cancer with a focus on node-positive disease and patients at elevated risk of recurrence, including invasive breast cancer-free survival outcomes.
- Node-positive breast cancer
- High-risk early breast cancer
- Recurrence prevention
- Invasive breast cancer-free survival
The therapeutic interest centres on endocrine-based treatment strategies in earlier-stage disease where long-term control is a key goal.
Brain metastases in breast cancer
Clinical activity includes brain metastases arising from ER-positive, HER2-negative breast cancer, reflecting interest in disease spread to the central nervous system.
- Breast cancer brain metastases
- Central nervous system involvement
- Metastatic ER-positive disease
This area links systemic breast cancer management with treatment needs in patients whose disease has extended beyond the breast and lymph nodes.
Combination endocrine and targeted therapy
Research covers combination therapy approaches in metastatic breast cancer, including pairings with mTOR inhibition and CDK4/6 inhibition.
- Endocrine therapy combinations
- mTOR-targeted treatment
- CDK4/6 inhibitor combinations
- Metastatic hormone receptor-positive disease
These studies reflect a therapeutic focus on overcoming resistance mechanisms in hormone receptor-positive breast cancer.
Platinum-resistant ovarian cancer
Additional research activity includes platinum-resistant ovarian cancer, addressing disease that no longer responds adequately to standard platinum-based treatment.
- Ovarian cancer
- Platinum resistance
- Treatment-resistant gynecologic cancer
This area broadens the sponsor’s oncology portfolio beyond breast cancer into difficult-to-treat gynecologic malignancy.
